This, namely, affects the exclusion of patients in the advanced NPDR/PDR with vitreous hemorrhage and intravitreal treatment within the past 6 months, as anti-VEGF treatment can affect the levels of cytokines [59]. The gene discussed is VEGFA; the disease is vitreous hemorrhage.